Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Neutral 67.4%

Neg 0% Neu 67.4% Pos 0%

Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.